Current Therapeutic Research - Clinical and Experimental 
Journal Title
- Current Therapeutic Research - Clinical and Experimental
ISSN
- P 0011-393X | 0011-393X
Publisher
- Excerpta Medica, Inc.
- Excerpta Medica
Listed on(Coverage)
| JCR | 1997-2012 |
|---|---|
| SJR | 1999-2019 |
| CiteScore | 2011-2019 |
| SCI | 2010-2012 |
| SCIE | 2010-2013 |
| SCOPUS | 2017-2020 |
| DOAJ | 2017-2021 |
| EMBASE | 2016-2020 |
OA Info.
| OA |
based on the information
|
|---|---|
| Keywords | drug therapy, applied health economics |
| Review Process | Double blind peer review |
| Journal info. pages | |
| Licences | CC BY, CC BY-NC-ND |
| Copyrights | No |
| DOAJ Coverage |
|
| Subject(s) | Medicine: Therapeutics. Pharmacology |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- USA
Aime & Scopes
- Current Therapeutic Research (CTR) is a Gold Open Access, PubMed/Medline indexed, online-only journal. CTR focuses on the rapid publication of peer-reviewed original reports of all aspects of therapeutics, including papers presenting unexpected and/or negative results. We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: /// Interventions designed to understand or improve human health, disease treatment or disease prevention; /// Studies that focus on problems that are uncommon in resource-rich countries; /// Research that is under-published because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); /// Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; // Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.